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ABSTRACT 
Newly-developed  genetic  tests  based  on  restriction  fragment  length  polymorphisms 
(RFLPs) promise  to facilitate  the early  detection  of genetic diseases.  Several  such tests 
are  now available  for the prenatal  detection  of cystic  fibrosis  (CF), a common  and  costly 
disease.  The tests  for  CF are currently  limited  to prenatal  diagnosis  in siblings  of a 
victim  of CF.  Direct  gene  probe  tests,  which  have yet to be developed  for CF,  would be 
applicable  even in families that  have not  already borne a  child with the disease.  We  examine 
the  costs  and benefits  of prenatal  testing  for cystic  fibrosis  using  existing  RFLP-based 
tests  and using a  hypothetical  direct  gene probe test.  We find that even an expensive  RAP- 
based testing  program  produces  substantial  net  benefits, because  it is applied in pregnancies 
in which the risk of CF  is 25%.  If a  direct  gene probe test  is applied  in all pregnancies, 
it will  need  to be much  less  expensive  to generate  net benefits,  and it will  lead to the 
abortion  of  many normal  fetuses  unless  it  is  highly specific.  Because  these new tests  are 
likely  to generate  substantial  savings  in medical  expenditures  and  to  increase  lifetine 
earnings,  parents of  CF-affected  children may  be subjected to  strong pressures to participate 
in prenatal  testing programs  and to  abort  fetuses that test positive.  It is imperative  that 
the  ethical  dilemmas  arising  from this promising  screening  test be  discussed  openly  before 
it becomes  widely  available. 
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Stanford,  CA  94305 INTRODUCTION 
Affected  individuals,  their families,  and  society  as  a whole  share  the  burden  of 
genetic  diseases.  Many  victims  of  these  diseases die  during  infancy. Others  face a lifetime 
of intensive  medical treatment,  frequent  hospitalization,  and severe activity  restrictions. 
The monetary  cost to the  patient's  family  and  to society  can be staggering.  Less  easily 
quantified  but also important  is the psychological  toll;  children  who have genetic diseases 
often suffer  impaired psychosocial  development  and their parents have high divorce rates.1ZS 
Few  of  the  more than 3000 known  human  genetic diseases can be prevented  or  cured.4 However, 
recent advances  in molecular  biology have led to the development  of prenatal  tests  that can 
detect  these  diseases,  even when  their precise  etiologies  and  specific  genetic  defects  are 
unknown. The  new tests, based upon  restriction  fragnent length polymorphisms  (RFLP5), promise 
to  determine  with  near  perfect  accuracy  whether  the fetus  is  afflicted  with  a  genetic 
disease. 
Such tests  are now  available  for  the  prenatal diagnosis  of  one of  the nost  devastating 
of all  genetic  diseases,  cystic  fibrosis  (CF).  This  astosomal  recessive  disease,  which 
affects  the  sweat  glands,  pancreas,  lungs,  and  other  organs,  is  incurable  and  costly.5'° 
Pulmonary  exacerbations  can  cost  nore  than $18,000  if treated  in the  hospital,  and  older 
children  may have these  episodes  several  tines  in a year.7 While  extensive  supportive  care 
has  prolonged  the  survival  of CF patients,  most die by their  mid-twenties.  CF is the cost 
common  of all  lethal  genetic  diseases  among  cascasians  in this country,  with  an incidence 
of about  1  in 2,000 births.89'5'1  The 257. risk of CF  in  subsequent  pregnancies  deters  many 
parents  of  children  with CF from  bearing more  children.72 Because many of  these  couples  are 
eager  to reduce this risk  of CF  and give birth to unaffected  children,  CF is a  prime  target 
for genetic  testing.  At one  CF center  92% of the still-fertile  parents  with CF-affected 
children  expressed  interest  in prenatal  diagnosis  and more  than 70%  claimed that they  would have more children  if an accurate  prenatal  test were available.'3 
We report here the  results of  an analysis of  the costs and benefits  of  prenatal  genetic 
testing  for cystic  fibrosis.  Our analysis  is limited to the  monetary  consequences  of  CF -- 
the direct  health care  costs of  the  disease and the effects of lost income due to death and 
disability.  The  analysis  of  this test differs from many cost-benefit  analyses  sf  health care 
because  the disease  is incurable  and  can only be prevented by  averting  the birth of  affected 
children.  The financial  impact  of the test depends  on choices  made  by parents who discover 
that their  fetus  is affected.  If they choose to have more children,  carrying  to term only 
those  fetuses  who test negative,  population-wide  earnings  will  rise  more  than  if they 
terminate  or  avoid  subsequent  pregnancies. 
We also evaluate  the  consequences  of  testing with  a  direct  gene probe test. Such tests 
are less  cumbersome  and may replace  RFLP testing. Although  direct  gene  probe  tests for CF 
are  not currently  available,  they could be produced soon after the  CF  gene  is  identified  and 
sequenced,  a  breakthrough  that many  experts believe is insninent.'4'5  Unlike  RFLFs, which  can 
only  be used when there  is  a  family  history of  the disease,  direct  gene  probes will  allow 
detection  of  the disease  gene in  members  of the general  population,  whose risk of bearing 
a  child  with CF is about  1/500th as great. Universal application  of  a highly accurate  probe. 
if fetuses  who tested  positive  were aborted,  would  also prevent  nearly  all  births  of CE- 
affected  children. 
THE  NEW  GENETIC  TESTS 
Genetic  tests  for the  prenatal  detection  of CF employ  restriction  fragment  length 
polymorphisms  of the DNA  sequences  near  the  CF  gene to track disease  inheritance  in 
families.'6  Similar tests  have been  developed  for  the detection  of  sickle  cell  anemia, 
polycystic  kidney disease,  Huntington's  disease,  and Duchenne's  muscular  dystrophy.'7161023 
These  tests  allow families  to determine  the  disease status of a fetus  (affected,  unaffected, 
or heterozygous  carrier)  as  early  as the ninth week of pregnancy.  Because  RFLP  testing requires  genetic  information  from  family  members  to determine  whether  the fetus  has  the 
disease,  samples must be obtained  from each parent, an affected  sibling  (or other  affected 
relative),  and from  the fetus at  risk. These  requirements usually nake it impossible  to apply 
RFLP testing  to avert  the birth of the  first CF-affected  child  in a family. 
RFLP testing  uses  the  individual's  pattern  of DNA  fragments  as a marker for  the 
presence  or absence  of the CF gene.  It places  these  patterns  in the  context  of the known 
disease  states  of the family  members;  thus,  an exact  match  of RFLP5  from the  affected 
relative  and  the  fetus  indicates  that the  fetus  is probably  affected  as well. To increase 
the probability  that the test will be able to  discriminate  between the parental  chromosomes 
and determine  which  chromosomes  carry  the disease gene, the genetic  probes and  enzymes  used 
in RFLP testing  are chosen  to be highly polymorphic  in the testing population.  The ability 
to distinguish  the parental  chromosomes  is  called informativeness.  An uninformative  test, 
because  it does  not indicate  whether  the  fetus  inherited  a pair of the  disease-carrying 
chromosomes,  does not  influence  the probability  that the fetus  has the disease. 
The  tightness  of the linkage  between  the markers and the CF gene locus  also affects 
the performance  of  the test. For example,  in a  given  family the test may be informative  for 
two markers  that appear on  both sides of  the CF gene. These flanking markers make it possible 
to detect whether  recombination  has occurred  between the CF gene and the test probe  binding 
site.  Similarly,  nearness  of the markers  to  the  CF gene reduces  the  probability  of 
recombination  and strengthens  the association  between the marker  and the gene.  Commercial 
laboratories  claim  to have accurate  and informative tests because they use  multiple  flanking 
markers;  for example,  Collaborative  Research  of  Waltham, Massachusetts,  uses twelve  probes 
which  flank,  and  are at varying  distances  from, the CF locus.2' 
The RFLP-baoed  prenatal  tests  for CF appear to be substantially  more accurate  than the 
alternative,  enzyme  assays, which  are neither sensitive nor specific.°''°°  Despite the  great 
promise  of the new tests,  they  have significant  drawbacks: they are expensive  and they can 
predict  disease  status  incorrectly.  In  routine  use,  errors  that  occur  in  laboratory 4 
processing,  such as mislabeling  specimens,  might  occur.  Secondly,  if recombination  occurs, 
the  RFLP patterns  might no longer  be linked  to the  disease  gene.  Because  the  rate  of 
recombination  is roughly  proportional  to the distance  between  tho marker  and  the  disease 
gene,  and because  most  laboratories  use  markers  that  are near the disease  gene,  such 
recombination  is unlikely  for most of the available  tests.  Third,  the mutation  causing  CF 
might  not be at the same locus  in all pmrsons, although  this is unlikely.24 Failure to obtain 
fetal tissue  would  preclude  testing,  but ongoing  improvements  in chorionic  villus  sampling 
and amniocentesis  are likely  to diminish  both the  failure rate and the incidence of  maternal 
and fetal  complications.25  It  is also  possible  that  a  test  will  he noninformative  in  a 
particular  family,  but most labs now  claim  that their tents  are  informative  in at least 97% 
of the families  tested. 
Incorrect or  equivocal  test results can have fateful consequences.  False positive tests 
lead  to the  abortion  of unaffected  fetuses,  while false  negatives  lead  to the  birth of 
affected  children.  The  frequency  of these  errors  is  unknown.  No published  studies  have 
reported  the  sensitivity  and specificity  of  RFLP  tests  in human  populations.  Preliminary 
results  of testing  CF-affected  children  and their siblings  suggests  that the  tests  are 
extremely  accurate  (personal communication,  H. Kazazian,  Johns  Hopkins University),  and  it 
is  assumed that over 99% of test results  are correct.2627 However,  whether  these  excellent 
results will  be  duplicated  when the tests  are used on a wider  scale  is unknown. 
For  each  1,000 pregnancies  tested with  a test that  is 99% sensitive  and specific,  745 
of  the fetuses will test negative,  of which two would  be affected;  255 fetuses test positive, 
of which  seven  would be unaffected.  Thus,  nine  of  every  1,000  tested  fetuses  will  be 
misdiagnosed,  two of  which  will  have CF. Because the genetic  tests  are the only technology 
that  can  reliably  determine  whether  a  fetus had CF,  it would be difficult  to verify  the 
false-positive  rates of  these  tests.  Eventually,  however,  the false-negative  fetuses  that 
are carried  to term will  be  recognized  as misdiagnoses. 5 
METHODS 
POPULATIONS 
Prenatal  testing  for  CF  based  on  RFLPs  can  only  be applied  in families of  CF-affected 
individuals.  In  this population,  the probability  that each pregnancy will yield  a  CF-affected 
infant  (the pre-test  risk)  is 0.25. We  assume that only women who  would consider  abortion 
will undergo testing.  Since the Cystic Fibrosis Foundation  currently  has over 15,000 patients 
in its registry,  thousands  of  American  families are candidates  for testing.  For the analysis 
of a hypothetical  direct  gene probe test applied to the general  population,  we assume  that 
one  in twenty  caucasians  is  a heterozygous  carrier  of the  CF gene,  so that one of every 
1,600  pregnancies  will  be affected.6 
COSTS  OF CF 
Table  1 presents  some published estimates of  the medical expenditures  for  CF; although 
the estimates  vary  widely,  it is  clear  that  the  amounts  involved  are  many thousands  of 
dollars  per  patient  per year.  The extraordinary  costs  of caring  for CF patients  arise  from 
frequent  hospitalizations  and the  need for expensive medications,  such as antibiotics  and 
replacement  pancreatic  enzymes.  We assume a constant expense of  $8000 per  year for CF-related 
health  care. We use 25 years  as our  estimate  of  the  mean life expectancy,  based  on the  most 
recent  (1985) reports  of the Cystic  Fibrosis  Foundation.28  Annual  costs  of care,  and all 
costs and earnings  in future  years,  are discounted  at  5%.  These  figures  are  conservative 
estimates  of  the total costs of  care  of  cystic  fibrosis,  since both life expectancy  and the 
cost of the therapy  have been  increasing. 
In  cost of  illness  or cost-benefit  studies,  costs  are usually  divided into  two 
categories,  direct  and indirect.29'30  A comparison  is always  implicit  in the cost estimates; 
usually the comparison  is to  the  expenditures  and earnings  that  would  accrue  if  the  disease 
could  be  eradicated  costlessly.  The direct  costs  of cystic  fibrosis  include  those  of 
testing,  abortion  or  birth, health  care, and all costs associated  with preventing  or  treating the illness.  rndirect costs  are the earnings lost due  to disease-related  disability  and early 
death.  When  compared  to  unaffected  individuals, CF  patients  have  brief  lives, frequent  work 
absences  (if  they  survive  to  working  age  and  enter  the  labor  force),  and-  low  (often 
negligible)  expected  earnings.  We define  the  change  in  indirect  costs,  or the earnings 
benefit  of testing,  as the difference  between the expebted  value of (discounted)  lifetime 
earnings  under  a testing  strategy  and under  a no  testing  strategy.  Lifetime  earnings  under 
a  testing  strategy  depend  on additional  decisions  made  by the  parents.  For 'example, if a 
fetus tests  positive,  the family opts  for abortion,  and they proceed to bear a  normal  child 
in a subsequent  tested pregnancy  ("replacement"  of affected and  aborted fetuses), 'the change 
in indirect  costs  is the difference  between the lifetime earningsof a  normal  child  and the 
lifetime  earnings  of an affected  child.  If they opt to abort  and do not have  another  child 
("no  replacement"),  the  earnings  benefit  of testing  will  be the  difference'between  the 
earnings  of an  abortus  and the  discounted  future  earnings  of an  affected  fetus.  Pain. 
suffering,  and other  non-monetary  inipacts  of the disease  are not  included 
- 
To  compare  the  lifetime  costs  (direct  and  indirect)  for  affected  and  unaffected 
children,  it is necessary  to account  for the total  lifetime health  care costs of  unaffected 
individuals  as welt as the decreased  earnings  of individuals  with  CF.  Therefore,  the  net 
present  value of an unaffected  individuaFs  lifetime  health  care costs  is subtracted  from 
his  or  her  expected  lifetime  earnings  to get  the incremental difference  in totalcosts (both 
indirect  and  direct)  between  unaffected  and  affected  individuals.  We  estimated  average 
lifetime  health  care  costs for the general  population  by using  age-specific  annual  health 
expenditures  from the Consumer  Expenditure  Survey,3' age-specific  mortality'rateo  from  U.S. 
life tabTes,"  and an inflation-adjusted  rate of  discount  of 5%.  These  figures  inply  that 
the average  discounted  value  of'iifetime  health  expenditures  at birth  is 5ll,l63  This 
figure  appears  in Table  2, as doall the dollar  amounts used  as central  estimateo  of the 
costs and  benefits  in our analysis. These cost estimates are  from  the providers  of  the tests 
themselves,  local hospital  charges,  insurance reimbursements,  and published reports. Although the  total  lifetime health  care expenditures  of  unaffected  individuals  are large, most of  them 
occur in the  later  years of  life.  These  delayed costs  add little  to the  present  value,  or 
discounted  lifetime  costs of care,  since  even  large costs  add  little  to the present  value 
if they are delayed  for  many  years  and discounted  at a 5%  annual  rate. 
COSTS  OF  TESTING 
Prenatal  RFLP  testing  requires  tissue  from the mother,  father,  affected  relative,  and 
the fetus  at risk.  Peripheral  blood  provides  the  DNA  for  all the family  members  but  the 
fetus,  and the cost of  venipuncture  is assumed to be negligible.  Costs for testing the  tissue 
vary: Collaborative  Research  currently charges $1,100 to  test the  family ($800 for the  family 
members  and $300 for the fetus); Baylor University  charges $600/family  (or $150/sample);  and 
Integrated  Genetics  of  Framingham,  Massachusetts  charges $850/family.  (Although we  have  used 
data  from  Collaborative  Research  as  the  basis  of our  analysis,  this  does  not imply  our 
endorsement  of  this or  any other  specific  assay.) 
There  are two methods of obtaining  fetal tissue  for testing.  The  test  in most common 
use  is  amniocentesis,  which can  be performed  beginning  at  about  the  sixteenth  week of 
pregnancy.  Chorionic  villus  sampling  (CVS)  is a newer  procedure  that  can be performed  as 
early  as the ninth or  tenth week  of  pregnancy.33 The base-case analysis  assumes that CVS will 
be used,  because  many  families  undergoing  prenatal  genetic testing  are likely to prefer  the 
earlier  diagnosis  it provides.  In addition  to these  costs,  a slight  risk of  miscarriage  is 
associated  with  each of these  procedures.  Aside  from the risks  of venipuncture  itself,  no 
further  risks  result  from  obtaining  tissue  from family  members. 
TEST CHARACTERISTICS 
Some  laboratories  that  perform  these  tests,  such  as Collaborative  Research,  do not 
report the results  of the test as  positive  or  "negative."  Instead,  they  report  the 
probability  that  the  fetus  will  have CF.  Although  the test  performance  and  the  operating 8 
characteristics  have not  been  studied  prospectively,  we assume  that the test  is extremely 
accurate,  as the laboratories  claim,  and for the purposes  of  our calculations,  we  estimate 
both  the sensitivity  and specificity  to be 0.99. We  then show how  the  results of  our analysis 
change  as we modify  these  assumptions  about  test performance. 
INCORPORATING  COSTS  AND  PROBABILITIES  INTO A  DECISION  FRAMEWORK 
Our analysis  explores  the  consequences  of two major  decisions:  whether  to test  and 
whether to abort.  A family  that  decides  to abort a fetus  testing  !positive faces  a third 
decision:  whether  to "replace" the  aborted fetus with  another pregnancy.  The outcomes,  their 
values,  and the probabilities  of various  events  are schematized  in the decision  tree that 
appears  in Figure  The upper  two-thirds  of the tree shows the costs  and  outcomes  based 
upon a decision  to test;  the lower  one-third  is based  on a decision  not  to test.  Following 
conventional  notation,  this decision  tree represents  "decision  nodes," or points  at which 
actions  must  be taken  by the decision  maker,  ss boxes.  Circles  represent  "chance nodEs," 
or points  where  the outcome  is uncertain.  The figures adjacent  to  the chsnce  nodes  are the 
probabilities  of  each of  the outcomes.  We  explore the  decision  problem  from  the  perspective 
of  a policymaker  (e.g., an insurer or Medicaid  official deciding  whether  to offer  or require 
these  tests). The  policythaker  weighs  the  relative costs of  the  options  and the values of  the 
possible  outcomes.  The considerations  for a woman  (or family)  who  has had a child with CF 
are displayed  in Figure  1. First,  note that the pre-test  probability  of  CF is 0.25. If  the 
test is 99% sensitive  and specific,  a positive test result will be  obtained  25.5 percent  of 
the time and a negative  test iesult  74.5 percent of the time. The post-test  probability  of 
disease,  given  a  positive  test result,  is 0.97,  and  the  probability  of disease with  a 
negative  test result  is 0.003. 
The  costs  and outcome probabilities  associated with the decisions  on  Figure  1 are based 
on  the  cEntral estimates  (Table 2) and the following assumptions:  1) fetuses testing positive 
are aborted;  2) under  the replacEment  condition,  the families  attempt  to conceive,  testing 9 
subsequent  fetuses  and aborting  those  that test positive,  until they  conceive  a fetus  that 
tests  negative;  3) under  the no replacement  condition,  the families  do not  attempt further 
pregnancies  if the fetus  tests  positive  and  is aborted;  4)  fetuses  testing  negative  are 
carried to term; and  5) families  that refuse  the test  carry  pregnancies  to  term. The  dollar 
amounts on the right  side of the tree are the sums of  the  costs  and benefits  for each of  the 
associated  outcomes.  The  expected  value of  each branch  is the  product of its probability  and 
the  costs  incurred in  reaching  that branch (testing, abortion, live  birth, and CF  health care 
suewned  as direct  costs,  and lost earnings  and disability  added as indirect costs); thus,  one 
can  work  back  to estimate  average values  for the decisions  preceding  the terminal  branches. 
This  results  in the  numbers  under  the words ]j  and No Test;  these  numbers can be used to 
compare the expected  values  of testing and not testing. 
A separate  analysis  was performed  on hypothetical  data  for a direct  gene probe  that 
could be applied  to all pregnant  women  (see Appendix).  The central  assumption  is that the 
test would  cost  $10. Because CF can only be inherited if  both parents are carriers, we  assume 
that the least  expensive  way to perform such pregnancy  screening  would be  to test only  one 
member  of a couple,  then test  the  spouses of those who test positive  (sequential  strategy). 
An alternative  approach,  testing all fetuses, would  require performing  amniocentesis  or  CVS 
for every  pregnancy,  and would  be prohibitively  expensive unless these  procedures  were being 
performed  for  other  reasons.  We further assume that the sensitivity  and specificity  of  the 
probe would  be 99%. Using  these  assumptions,  we calculate  the potential  costs  and benefits 
of  such testing,  and show how the  estimated  benefits  vary as we  alter  the assumptions  about 
the costs of the hypothetical  probe, the test accuracy,  and other  uncertain  quantities. 10 
RESULTS 
NET BENEFITS  OF  TESTING  - 
RFLP-based  testing.  Figure 
1  illustrates,  is  the  form  of a decisiontree,  the 
consequences  of testing.  The cost figures  are in 1985 dollars,  and are estimated  on aper 
fetus basis.  Negative  values  are negative  costs  or, equivalently,  positive  benefits.  The 
expected  value of  both  the direct  and  indirect  costs  of  testing  are  largest  with 
"replacement"  of all  fetuses  aborted  after a positive  test. Since  the desire  to give birth 
to unaffected  children  is the primary  reason  for  testing,  individuals  who choose  testing 
would  be expected  to pursue  the replacement  strategy. The calculations  for the replacement 
strategy  are based  on a  maximum  of four cycles of testing and attempted  conception;  because 
25.5% of fetuses  test  positive  in  any  iound  of testing,  fewer than  half  of 1% of the 
families  will need to go through more  than four rounds of  testing  before conceiving  a fetus 
that tests  negative.  Values  for the total  costs of testing with replacement  appear  as the 
upper of  each  pair of dollar values  on  Figure  1  (values  without  replacement  are  in 
parentheses  below).  The expected  benefit  of testing  is more than  $145,000,  compared  to 
aborting  the  pregnancy.  Compared  to  abortion:  giving  birth  tO  a child  without  prenutal 
testing  produces  a  financial  benefit  of over  $109,000.  Even  in this  high  risk  population 
three-fourths  of the  children  will  be unaffected  and have  normal  lifetime  earnings.  The 
impact  of  testing,  then,  is the difference  between these  expected  values,  or about  $35,000 
per  pregnancy.  Compared  to giving  birth at  each pregnahcy,  a family that chooses testing with 
a reØlacement  strategy  generates  greater  benefits  primarily  because  nearly  all  births  are 
free of the curtailed  earnings  and excess  health costs  of CF. 
The benefits  of testing  are smaller  - about $25,000 per fetus  -- if the family  does 
not opt for  replacement.  This figure  represents a  25% reduction  in the cost  of  CF care. Part 
of this reduced  cost comes from the decreased  number of live births  for tested  pregnancies 
(all  untested  pregnancies  go to term),  but  birth  costs are a small  fraction  of the  total 
health  care costs  for CF-affected  fetuses. The  $10,000 difference  between  the two strategies 11 
is the tradeoff  between  increased  earnings  of  unaffected  fetuses  born  if families  replace 
pregnancies  until testing  is negative  and the increased costs of  repeated  cycles  of  testing. 
Consequently,  testing  is economically  preferred  over  not  testing  and  replacement  over  no 
replacement. 
If only the direct  costs  are considered,  the least  costly  option  would be to abort 
all  fetuses  so that  no birth,  testing,  or health care expenses  would be incurred.  The fear 
of dauntingly  high  direct  costs  led  many  families  to use  contraceptives  or to abort  all 
pregnancies  prior to the  advent  of  prenatal  testing. However, this strategy has  high indirect 
costs,  since  the lost  lifetime  earnings  of the  unaffected  individuals  (estimated  to  be 
$1g8,000  per  fetus)  far outweigh  the expenses of birth and health  care. If  only earnings  or 
indirect  costs  are considered,  one  would  choose not to test because testing  may  lead to the 
abortion  and  loss  of earnings  of some  unaffected  fetuses.  When  both  types  of costs  are 
considered,  testing  reduces direct  costs  while  keeping earnings  high. 
Population-wide  carrier  screenino.  Under  the central  assumptions,  the  net  benefits 
of population-wide  screening  with a hypothetical  direct gene probe  are small.  The benefits 
depend  on gene  prevalence,  costs  of testing,  and accuracy.  At a relatively  small  level  of 
error, population-wide  screening  will be unacceptsble because many unaffected  fetuses would 
be aborted.  In addition,  because  the majority  of  CF patients  are born to families  that have 
no past history  of the disease,  compliance  with testing  programs  will need  to be extremely 
high in order  to decrease  the incidence  of  CF. 
Assuming  that  the  test  has  a sensitivity  and specificity  of •gg,  and that the gene 
prevalence  is  1 in 20, Figure  2 shows  how the net  benefit  per couple  tested varies  with the 
cost of the test.  A  $10 test would  produce net financial  benefits  of  $50 per  tested  family; 
if the test cost  slightly  more  than $50, it would  generate  net costs. 
The  prevalence  of  the  CF  gene  alters both the efficacy  of  the  test and the net benefit 
of testing.  In the high  risk population,  very few  errors  in diagnosis  will  occur.  In the 
general  population,  a screening  test with the same sensitivity  and specificity  will  result 12 
in more  misdiagnoses.  For example,  the  RFLP-based test in families  with a prior  history of 
CF results  in misdiagnosis  less than 1% of the time.  In the general  population,  where  the 
risk  is approximately  0.06%,  there  will  be 29 falsely  negative  and  19  falsely  positive 
results  per 1,000  tested  fetuses,  for an  error  rate  of almost  5%  (see  the  Appendix). 
Therefore,  the  successful  application  of prenatal genetic testing  in high risk families with 
one or more CF-affected  children  does  not  imply that  such  a  test  will  be useful  in other 
populations. 
SENSITIVITY  ANALYSIS 
The values  of several  parameters used  to  cal cul ate the costs  and benefits of prenatal 
screening  for  CF  are  uncertain.  We  assessed  the  sensitivity  of  our  findings  to  the 
assumptions  about  the  values  of  key parameters,  including  the  test  characteristics 
(sensitivity  and specificity),  lifetime earnings,  and the costs of  testing,  abortion,  birth, 
and  health  care for both CF-affected  and unaffected  individuals. 
RFIP-based  testing.  The net benefits  of testing,  assuming  that  parents  attempt  to 
conceive  another child after aborting  a  fetus which  tests positive  (i.e., replacement),  range 
from  about  $9,000  if CF does  not generate  any excess  health  expenditures,  to over  $35,000 
if CF care costs  $8,000  annually,  to over $75,000 if CF care costs  $20,000  annually.  The 
net  benefit  of RFIP-based  testing  without  replacement  is  about  $12,000  less than  for the 
replacement  strategy  at any level of cost of CF care;  the net benefit  is positive  under  no 
replacement  if  CF care costs  more than  about $1,000  annually. 
As Figure 3 demonstrates,  the net benefits of  testing  rise with the lifetime  earnings 
of  an unaffected  individual  if the  parents attempt replacement.  Net benefits decline slightly 
with earnings  under  a policy  of no  replacement  because  falsely  aborting  a  normal  fetus 
becomes more costly  as lifetime  earnings  rise. 
A test that is frequently  noninformative  produces  smaller  benefits,  on average,  than 
a highly  informative  test.  The  diminution  in benefits  that results  from  noninformativeness 13 
depends  on actions that the  parents  take when they confront  a noninformative  test.  The  net 
benefits  are  always greater  if  the parents opt against abortion  in this situation,  but even 
if  they  choose  to abort when the  test is noninformative,  the test generates  net benefits  as 
long as it is informative  about 85% of  the  time or  more (Figure 4).  Each of the commercial 
laboratoriei  that we  contacted claims that  their test's informativeness  substantially  exceeds 
this value. 
Although  the benefits  of using a screening  test depend  on the accuracy  of the test, 
as reflected  in the sensitivity  and  specificity,  the  benefits  of CF testing  change  little 
with  test accuracy  in the  range of relevant  values.  These  tests  are highly  sensitive  and 
specific,  and  the RFLP-based  tests are applied in a high-prevalence  population.  As Figure 
5 demonstrates,  the net benefit  of testing  changes little  as the test sensitivity  or  test 
specificity  falls  from  1  to  .9;  if the  upecificity  is  1,  the net benefit  of  testing  falls 
from about  $38,000  to $32,000  as sensitivity  declines  from 1  to  .9;  the net benefit  falls 
somewhat  less  if the  specificity  declines  from  1  to  .9.  The  purported  sensitivity  and 
specificity  of  all commercially  available  testu are substantially  higher  than the lower end 
of the ranges  displayed  here. 
The net benefits  of  RFLP testing decline  little as the  cost of  testing increases;  even 
if it cost  $5,000  to test  a  family, the net  benefits of testing  would  exceed $20,000  with 
no replacement,  and $30,000 with replacement. 
Carrier  screening.  In addition  to the unknown  cost of the hypothetical  gene  probe 
test,  the sources  of uncertainty  in the estimates  of  the net benefits  of carrier  screening 
are  the  gene  prevalence  in the tested population and  the accuracy  of  the test. Figure 6  shows 
how the net benefit per  tested couple  for CF screening varies with  gene  prevalence  (assuming 
full compliance  and a  $10 test).  In  a population  with a  gene prevalence  of 1 in 40 (0.025), 
the benefits  of screening  are small.  If  the prevalence  is  1  in  20, the net benefit  exceeds 
$40 per couple. 14 
The test cost that is just high enough so that the benefits  of  a  testing  program equal 
the  costs  is called the threshold cost.  At this cost, the decision  maker will be indifferent 
between  screening  and  not  screening  the population.  Figure 7 shows the relation  between the 
threshold  cost of the screening  and the gene prevalence.  The benefits  exceed  the costs  of 
testing  as long  as the test costs  less than $100, if the gene  prevalence  is 70 per  1,000. 
If  the prevalence  is 40  per 1000, the  test  produces  net benefits  only  if it costs  less than 
$40. 
As  with  the  RFLP test, the accuracy of  a  carrier screening  test will strongly  influence 
the  net benefit  of a  screening  program.  Figure  8 shows how  the sensitivity  and  specificity 
affect  those  benefits.  As in Figure  5,  net  benefits  are positive  for the expected  accuracy 
for the test  (sensitivity  99% and  specificity  99%).  However,  the benefit  vanishes  if both 
sensitivity  and specificity  are less than  95%. 
DISCUSSION 
Although  they have not  undergone extensive clinical evaluation,  RFLP-baued  tests appear 
to  be highly  sensitive  and specific  assays  for genetic diseases.  For many of  the  csnditions 
that  they detect,  alternative  tests  are either  inaccurate or unavailable. 
Cystic  fibrosis  is perhaps the  most  promising  candidate for  prenatal  screening becausv 
it is common,  its treatment  is costly,  and it is ultimately  fatal.  Other  genetic  diseases, 
such  as some forms  of muscular  dystrophy  and lipid  storage  disorders,  usually  cause  death 
early  in infancy  and do not result  in several years of burdensome  expenditures  for health 
care.  Some  other  genetic  diseases,  such  as Huntington's  disease,  do not  cause  morbidity 
until  late in the  course of  the  disease,  so that the excess medical  expenditures  attributable 
to the disease  are small  compared  to the direct  costs of  CF.  A large  number  of other  fatal 
genetic  diseases  are  exceedingly  rare.  The intense  efforts  to develop  tests  for CF  are 
stimulated  by  its  importance  as a cause of suffering as well as  by  the  scientific  challenges 
it presents. 15 
Existing  genetic tests  for CF are limited to  families  that have already borne  children 
with the disease.  In this  population,  the  25% prevalence  of  disease  means  that  the tests 
will  misdiagnose  very few fetuses.  In  the general  population,  CF occurs  in only  about  one 
of  2,000  births. A  screening  test applied to  all fetuses would  need to be extremely  specific 
to  avoid  the  abortion  of many unaffected  fetuses.  The  costs  of fetal  testing,  and  the 
chances  for error,  could  be reduced  by first  testing  all pregnant  women,  then  testing  the 
spouses of those who test positive  for the gene,  and only testing fetuses after  both parents 
test  positive  (see Appendix).  Even this  strategy  would  require  a highly  accurate  assay. 
Furthermore,  the  cost  of averting  the  birth of a child with CF would be high  unless  the 
screening  test were inexpensive. 
While  RFLP-based  tests  usually cannot be applied until a  family  has borne a  child with 
the disease,  the families  that use  the tests can be confident that they will be able to bear 
unaffected  children.  If prenatal  testing  enables  these  families  to have nore children,  of 
whom two-thirds  will be  CF carriers,  the CF gene will become more  prevalent  among  adults of 
childbearing  age. Carrier screening  may  also  increase the gene prevalence  by increasing  the 
number  of childbearing  heterozygotes.  The prevalence  of genes  linked  to the CF gene  would 
increase  as well.  The long-term consequences  of the change in the  genetic  composition  of the 
population  are unknown. 
ETHICAL  ISSUES 
Increased  concern  about the  magnitude  of health  expenditures  motivates  the quest  for 
opportunities  to  lower  the costs of  treating  illnesses. The  new tests  for prenatal  diagnosis 
of  cystic  fibrosis  represent  such  an  opportunity.  The  government  programs  and  private 
insurance  companies  that  pay for  some  of the  costs  of cystic  fibrosis  will  have strong 
incentives to  pressure  parents of affected children  to participate  in screening prograns  and 
to abort  affected  fetuses.  Even when  the costs of testing  exceed  $1,000,  participation  in 
such  programs  will  generate  large  savings  for  insurers.  While insurers  and  government 16 
programs  might  not  compel  families  to submit  to testing and to abort affected  fetuses,  they 
could  deny reimbursement  for health  care  of the  "preventable"  cases  of CF.  Because  the 
disease  can only  be prevented  by aborting  affected  individuals,  many  people  will  object  to 
testing  and  its  implications.  Others  will  feel  that  the  large  savings  that result  from 
screening  justify  its  widespread  adoption,  and that there  is no social obligation  to pay for 
the  care  of a disease  that  could  have  been prevented.  It is likely  that  testing  will  be 
advantageous  for insurers  even in the  absence of coercion,  since  a  high percentage  of the 
families  at  risk  are  likely  to comply voluntarily.  Nevertheless,  in  the  absence  of  a 
consensus  on  these issues or  of  a  procedure  to  balance the  rights of  families  at risk against 
the costs to the  larger  population,  it is imperative  that these  implications  of screening 
be discussed  and evaluated  openly before  testing  becomes widely  available. 
A  direct  gene probe  test presents  somewhat  different  issues.  It could  sharply  reduce 
the number  of  CF births because  it could be applied to all pregnant  mothers,  not just those 
who had given  birth to an affected  child.  But  because  disease  prevalence  is low  in the 
general  population,  prenatal  testing  of all  fetuses  would  lead  to the abortion  of many 
unaffected  fetuses.  The sequential  strategy  described  above, which  tests  the fetus only if 
both parents are found to be  carriers, would sharply limit the number  of  false-positive  tests 
while  producing  a small  number  of additional  false-negative  tests,  compared  to  prenatal 
testing  of all  fetuses.  Regardless  of  the  strategy,  any  test applied  to  the  general 
population  would need  to be  relatively  inexpensive  to  generate a  net savings in health costs. 
Consequently,  there  is weaker  pressure  to test the  general  population  than to test affected 
families. 
Cystic  fibrosis  is one  of  many genetic diseases  that will  become targets  for prenatal 
testing  with novel  molecular  biology  techniques.  The strategies  that result  from prenatal 
diagnosis  of such conditions  need not be limited  to abortion,  but  might  include  lifetime 
monitoring  for signs of  disease  so that specific  treatment  could  be instituted  early.  Some 
fear that a "brave  new world"  of eugenics  will  be forged  from genetic  testing  programs. 17 
Parents who  seek the  "perfect child" might  abort fetuses with  mild abnormalities  or  handicaps 
that could  be detected  by prenatal  tests.  Whether  these  fears will  become  reality  depends 
on the  responsible  development  and  application  of genetic  tests.  While the risk  that  any 
genetic  test will be  misused  is real,  it must be balanced  against the substantial  benefits 
that the new tests  offer to families  plagued  by genetic  disease. 18 
APPENDIX:  THE EFFECTIVENESS  OF  A SEQUENTIAL  STRATEGY  FOR  POPULATION-WIDE  SCREENING 
One parent  is tested  first.  The second  parent  is  tested  only if  the  test shows  that 
the  firot  parent  is  a  carrier  of the  CF gene.  If both parents  test  positive,  the  fetus 
undergoes  testing  for CF. 
Assuming  that 1/20th of individuals  of child-bearing  age carry  the  CF gene, and that 
affected  individuals  are as likely  to survive to birth as other  fetuses,  approximately  one 
in 1,600  births  will result  in CF.  In  the following  calculations  we present  rates  per one 
million  pregnancies;  if  no abortions  are performed,  625 of these pregnancies  will  result  in 
the birth of an infant with cystic  fibrosis. 
If the sensitivity  and specificity  of a  direct gene probe  test are each gg%, the test 
yields  the outcomes  at  each stage of  testing  as described  in Figure  g. The remainder  of  this 
appendix  describes  how  the consequences  of testing were assessed. 
Stage  I  -- tasting  the  first parent: 
Test +  Test  - 
49,500  500 
g,soo  950,000 
5g,000  941,000 
The 2x2 table above shows  the resulto of  testing  in this population,  classified  by the 
true genetic  status of  the individuals.  Of  1,000,000 parents tested, there will  be only 500 
false-negatives  and 9,500  false-positive  test results.  A  false-negative  result leads to  no 
further  testing.  One of  every 80 false-negatives  at  the first  stage will  later  result  in 
the  birth of  an infant  with CF (1/20  chance of pairing with another  carrier,  multiplied  by 
1/4  chance  that a child  will  have  CF when both parents are carriers).  Consequently,  the 
500  false-negative  test  results  at Stsge  I  will  result  in the  birth of approximately  six 
CF gene + 




1,000,000 2,920.5  29.5 
560.5  55,489.5 
3,481  55,519 
The  59,000  spouses  of individuals  testing positive  in Stage  I  also undergo  testing. 
Of  these  individuals,  2,950  will  be carriers  of the  CF gene.  Approximately  30  of the 
carriers  will  test negative.  Since  about  16% of the  individuals  testing  positive  in Stage 
I were fal  ne-positives,  21% of the false-negatives  at Stage  II  (rather than 25%) will result 
in the  birth  of children  with CF.  Consequently,  false-negative  tests at  Stage  II result  in 
the birth of about 6 infants with  CF. 
Stage  Ill 
-  testing  the fetus: 
Test +  Test  - 
CF  ÷  606.4  6.1  612.5 
CF  -  28.7  2839.8  2868.5 
635.1  2845.9  3461.0 
Stage  III tests  the 3,481  fetsses  whose  parents  both tested  positive.  Because  560.5 
of the Stage  II tests  are  false-positives,  and because about  16% of the true  positives  in 
Stage  II are  spounes  of individuals  who  had  a false-positive  test  result  in Stage  I,  only 
2450.25  of the  3,481  fetuses  tested  are offspring  of  two carriers.  Thus the prevalence  of 
CF in  the Stage  III population  is 17.6%,  rather  than the 25% expected  in the offspring  of 
two carriers. 
19 
children  with CF.  All  positive  test results  lead to further testing  (Stage  II). 
Stage 11  -- testing the second parent: 
Test +  Test  - 






This  sequential  strategy  results  in relatively  few  false-positives;  despite  the  low 
prevalence  of  CF among  all births,  there will be only zg false-positive  tests  in Stage  III, 
meaning  that the  chances  of aborting  a normal fetus  because  of  prenatal  screening  would  be 
three  in 100,000  pregnancies.  There are six  false-negative  tests  in Stage  III;  thus the 
number  of  unexpected  births of affected  infants is about  ig (slightly  more than  six births 
resulting  from false-negatives  in each  stage of testing).  Consequently,  1,062,481  genetic 
tests  and 3,481  fetal tissue  sampling  procedures  (amniocentesis  or  CVS) were done to detect 
606 fetuses with  CF,  resulting  in the abortion  of  2g normal  infants and  missing  ig affected 
infants.  If each  test  cost $10,  and  amniocentesis  or CVS  cost  $1,000,  the  cost  per case 
detected would  be  $23,260.  A  less sensitive test would  have a  higher cost  per case detected, 
while a less specific  test  might  also be more costly  because  it would  result  in more Stage 
III testing.  Furthermore,  lower  specificity  would  lead to the abortion  of  more fetuses who 
did not have CF. 21 
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$  8,098  Estimated  mean  annual  expense  for  all  patients 
(1983) 
** 
$  5,328  Estimated  mean  annual  prescription  costs  for  the 
relatively  healthy  CF  patient  (1985)** 
* 
Results  of the CF patient registry.  CF Foundation,  1980 
** 
Result of the patient  survey, 1985. CF Foundation,  Baltimore,  MD. Table  2.  Central  Estimates  for  the  Costs  and  Benefits of 
Prenatal  RFLP  Testing  for  Cystió  Fibrosis 
(5%  discount  rate) 
Direct  Costs 
Sampling fetal DNA 
(chorionic  villus  sampling)  $  1,000 
Testing fetal DNA 
(Collaborative Research, Waltham, MA)  $  300 
Sampling  and testing family 
(Collaborative  Research)  $  800 
Abortion  $  500 
Birth  $  2,500 
Present value of lifetime costs 
of CF care ($8,000 for 25 years) 
(see Table  1  above)  $  11 2,752 
Indirect  Costs 
(Lost  Lifetime  Earninas 
Present value of earnings lost if 
an unaffected fetus is aborted 35  $  1 98,000 
Approximate  present value of 
earnings  of a CF-affected fetus 35  $  0 
Benefits 
Present  Value of the lifetime earnings of a 
normal child ($198,000) less the 
present value of the medical care costs 
of an unaffected child ($1 1,163) if an 
affected fetus is replaced with an 
unaffected one  31,32,35  $  186,837 Figure  1.  Decision  Tree for the Prenatal  Diagnosis 
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 Figure  9.  Sequential  Testing  Strategy for  Carrier 
Screening for  the  Cystic Fibrosis  Gene  in  the 
General  Population 
Screen  pregnancies 
in  the  general  population 
1,000,000 
Test  first  parent 
59,000  (+) 
Test  second  parent 
3,481  (+) 
Test  fetuses  of  at-risk 
parents 
635  (+) 







(-)  55,519 
Abort  fetuses  testing 
positive 